But is that not the main reason for doing a Phase 1 trial being to treat at varying dosage rates to see at what level is acceptable both for healing and for toxicity ?
However there was some research done by Collins et al that dosage rate should not be the main indicator as important to also look at the "probability" of a particular dosage rate being at an acceptable level of toxicity.
http://brb.nci.nih.gov/techreport/phaseIctd.pdf
- Forums
- ASX - By Stock
- KZA
- Ann: Anisina Confirmed as Effective Anti-Cancer Agent in-vivo
Ann: Anisina Confirmed as Effective Anti-Cancer Agent in-vivo, page-16
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online